Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3388MR)

This product GTTS-WQ3388MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3388MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8559MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ11837MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ10379MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ15500MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ6221MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ13784MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ1339MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-806
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW